People are microdosing GLP-1s for weight loss. Is it safe?
Summary
This episode explores the emerging trend of microdosing GLP-1 weight loss drugs, featuring experts Dr. Joey Madtingly and Dr. Jorge Moreno. They discuss the lack of clinical data supporting doses below FDA-approved levels and the risks associated with compounded medications from unregulated telehealth clinics. The conversation highlights concerns about unknown impurities, inadequate marketing disclosures, and the need for rigorous research to ensure patient safety.
Topics discussed
Sponsors and show introduction
The rise of microdosing GLP-1 weight loss drugs
Defining microdosing and the lack of clinical consensus
The evidence gap: FDA trials vs. microdose efficacy
Patient anecdotes and the challenge of funding research
Listener stories: Telehealth and self-managed dosing
Risks of compounded medications and unknown impurities
Sponsor break
The role of compounding pharmacies in the medical ecosystem
Marketing concerns and the issue of access and cost
Side effects for patients who do not meet obesity criteria
Listener story: Compounded semaglutide with B12 additives
Chemical interactions and the need for safety studies
Regulation, quality control, and telehealth pharmacy opacity
Final advice: Follow-up care and transparency with providers
Closing remarks and sponsor
Listen ad-free on Castria